KRT88P and autoimmune disease: In a study, it was reported that in patients receiving anti-TNF-α therapy with an indication of autoimmune disease, 9 out of 23 patients (39%) who were HBsAg positive at the beginning of treatment developed HBVr, but none of the 178 HBsAg negative/anti-HBc positive patients developed HBVr7.